Capricor Therapeutics, Inc. (CAPR) News
Filter CAPR News Items
CAPR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CAPR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CAPR News From Around the Web
Below are the latest news stories about CAPRICOR THERAPEUTICS INC that investors may wish to consider to help them evaluate CAPR as an investment opportunity.
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLACapricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States. |
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of the submission of its Biologics License Application (BLA) to the U. |
High Growth Tech Stocks To Watch In December 2024The United States market has remained flat over the last week but is up 29% over the past year, with earnings expected to grow by 15% per annum. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation while aligning with broader market trends. |
Capricor Therapeutics to Present at Upcoming Investor ConferencesSAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at the following upcoming investor conferences. Event:Piper Sandler 36th Annual Healthcare Conference (New York, NY)Presentation:Tuesday, December 3, 2024 from 11:30-11:55 a.m. ETFormat:Fireside chat, industry panel and one-on-one meeting |
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines AgencyMilestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular dystrophy in the European regionSAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the European Medicines Agency (EMA) has granted both Orphan Drug and Advanced Therapy Medicinal Product (ATMP) designation |
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where Capricor Therapeutics, Inc. (NASDAQ:CAPR) stands against other best multibagger stocks. November has been an eventful month so far for the market as the Fed cut rates by a […] |
Capricor Therapeutics Third Quarter 2024 Earnings: Misses ExpectationsCapricor Therapeutics ( NASDAQ:CAPR ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.26m (down 63% from... |
Q3 2024 Capricor Therapeutics Inc Earnings CallQ3 2024 Capricor Therapeutics Inc Earnings Call |
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue EstimatesCapricor (CAPR) delivered earnings and revenue surprises of -11.76% and 43.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Capricor: Q3 Earnings SnapshotSAN DIEGO (AP) — Capricor Therapeutics Inc. CAPR) on Wednesday reported a loss of $12.6 million in its third quarter. The San Diego-based company said it had a loss of 38 cents per share. |